Glucagon-like peptide-1 receptor agonist use in pregnancy: a review

A recent large observational study examined 938 pregnancies affected by type 2 diabetes mellitus and found no significantly increased risk of major congenital malformations in patients taking glucagon-like peptide-1 receptor agonists.

• Women with oligomenorrhea treated with glucagon-like peptide-1 receptor agonists may experience unplanned pregnancies due to successful weight loss.
• Animal studies have indicated potential adverse outcomes from glucagon-like peptide-1 receptor agonists during pregnancy, including decreased fetal growth and embryonic death.
• Current evidence from case reports and studies does not show a consistent pattern of congenital anomalies in infants exposed to these medications.
• The lack of data on maternal glycemic control limits the ability to draw definitive conclusions about safety during pregnancy.
• Patients are advised that there is insufficient evidence to predict adverse effects from periconceptional exposure to glucagon-like peptide-1 receptor agonists.

AI simplified